Published online Jan 14, 2026. doi: 10.3748/wjg.v32.i2.113810
Revised: October 1, 2025
Accepted: November 24, 2025
Published online: January 14, 2026
Processing time: 130 Days and 22.6 Hours
Data comparing the outcomes of hepatocellular carcinoma (HCC) ablation by multibipolar radiofrequency ablation (mbp-RFA) and microwave ablation (MWA) are lacking. This study compares safety and efficacy of the two techniques in treatment-naive HCC.
To compare the risk of local tumor progression (LTP) according to the technique; secondary endpoints included technique efficacy rate at one-month, overall sur
A bi-institutional retrospective analysis of patients undergoing treatment-naive HCC ablation by either technique was performed. Inverse probability of treatment weighting was used to compare the two groups. Mixed effects multivariate Cox regression was applied to identify risk factors for LTP.
A total of 362 patients (mean age, 66.1 ± 6.2 years, 308 men) were included, of which 242 (323 tumors) treated by mbp-RFA and 120 (168 tumors) by MWA. After a median follow-up of 27 months, cumulative LTP was 11.4% after mbp-RFA and 25.2% after MWA. Independent risk factors for LTP at multivariate analysis were MWA (hazard ratio = 2.85, P < 0.001) and tumor size (hazard ratio = 1.08, P < 0.001). Two-year LTP-free survival was higher after mbp-RFA than MWA regardless of size (< 3 cm: 96% vs 87.1%, P < 0.01; ≥ 3 cm: 87.5% vs 74%, P = 0.04). Technique efficacy rate was higher after mbp-RFA (94.1% vs 87.5%, P = 0.01). No difference was observed in major compli
Mbp-RFA leads to better local tumor control of treatment-naïve HCC than MWA regardless of tumor size and has better primary efficacy, while maintaining a comparable safety profile.
Core Tip: There is limited data comparing multibipolar radiofrequency ablation (mbp-RFA) and microwave ablation (MWA) for treating hepatocellular carcinoma (HCC). This study analyzed 362 patients with newly diagnosed HCC who underwent either mbp-RFA (242 patients, 323 tumors) or MWA (120 patients, 168 tumors). Results showed that mbp-RFA provided better local tumor control, with a lower local tumor progression rate (11.4% vs 25.2%) and a higher complete ablation rate (94.1% vs 87.5%) compared to MWA. The advantage of mbp-RFA was particularly significant for tumors larger than 3 cm, where MWA had a local tumor progression rate of 60.9% vs 21.6% with mbp-RFA. Despite these differences in efficacy, both techniques had similar major complication rates (9.5% vs 7.5%). These findings suggest that mbp-RFA is a more effective option for larger, treatment-naïve HCC tumors while maintaining a comparable safety profile.
